EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
about
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissuesSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerNew molecularly targeted therapies for lung cancerLung cancer chemoprevention: current status and future prospectsInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsUpdates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemopreventionPulmonary adenocarcinoma: a renewed entity in 2011Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway.Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops.Lung cancer cytology: potential pitfalls and mimics - a review.Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implantsImmunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Field cancerization in non-small cell lung cancer: implications in disease pathogenesis.Activation of oncogenic pathways in idiopathic pulmonary fibrosis.Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancersCharacterization of tumor progression in engineered tissue using infrared spectroscopic imaging.A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma.The BATTLE to personalize lung cancer prevention through reverse migration.QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer.An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsLung cancer in never-smokers.High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutationEvolving concepts in lung carcinogenesisCombinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancerLaricitrin suppresses increased benzo(a)pyrene-induced lung tumor-associated monocyte-derived dendritic cell cancer progressionSmoking and lung cancer: future research directions.Enriching the molecular definition of the airway "field of cancerization:" establishing new paradigms for the patient at risk for lung cancerPersonalizing lung cancer prevention through a reverse migration strategy.Transforming Cancer Prevention through Precision Medicine and Immune-oncology.Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.
P2860
Q24645724-F3D90AC8-1936-4D1D-AD58-5834C0ECD5B2Q24648133-B28E5C78-4560-4D8C-9885-5EA3D2DFF055Q24680988-C823D4F0-25D1-4243-848E-4AC75854DFBBQ26995495-8FAE96A5-6EFB-485E-A8F4-D4F5EEB18587Q28303718-91E9488E-8CB0-459C-9302-595E980968CCQ28304646-AE5F9521-CCAF-4DEF-A836-386D5816F107Q28388931-6D699CC8-FA20-4599-8BF0-382CF9CE9696Q28395348-A03D479F-77EA-41CC-A2E0-7ACB82673F13Q33569956-5931AE7F-DCCA-40FD-91D6-EC7789987F62Q33769820-C23912AB-CE43-4015-812B-FE3DE6878B2AQ33861083-765C459C-4099-4B3B-8EC5-A0F779DCB9B4Q33862255-46E7D54A-43C7-449E-91D7-95A368055F59Q33944679-CCD3ADEE-30B1-407C-8A69-281DD5A76210Q34062498-624299C6-98A3-4752-9F67-F20732FCE5C7Q34160907-A806164E-85AE-49AF-BD1F-0F4CC80B53DBQ34272221-593F70E6-6716-4145-BA5D-0438C7D98663Q34478556-F2658658-DB1B-4040-8D78-F7BFEA88F51AQ34504623-38F07C66-F4AD-426B-B844-C04B029EF0C4Q34539840-4F99D706-DB07-4896-BB20-3EB4A0217B2EQ34733314-3BCC0F40-BD24-43CE-B1F1-8AB07072EFEAQ34994448-58A8AF05-376A-4C12-AC2F-A2090BBE6BC1Q35113376-BD66CA06-4F2E-46E6-AC2D-902AD2CC1BD5Q35208501-8CEC86DD-449A-46F9-B45D-30B17B521775Q35813632-5F8BB61E-20A3-442C-ADBA-31D64BB8BF36Q35883386-8C4CF766-84F8-4D22-BF32-348A5059470CQ35920986-B3903B5E-C84C-4CFD-8B5D-CC1E1E324DD2Q36014004-29FA882E-909A-48A7-89EF-5F93F56E68AEQ36025680-CACF27FA-A08D-4E2D-BB84-3F92AC50ED5BQ36026075-386BA5EF-6C54-4254-8BC6-8C397AFBEB58Q36059727-E5D1ED97-DF46-47D1-9468-51746F8641C1Q36178320-CF09D099-7CB2-4313-9DA0-273EE7E590D2Q36189311-759F1824-99CB-4465-B85F-7508E8FA0C3DQ36477753-5D96F69B-656D-44EF-B10F-91E19E9AA8C2Q36640684-FDF74451-79BD-490B-8480-E8888B345798Q36895457-10708FFB-FB04-43AD-B05C-7AC4F22D8E9DQ37029665-9C8C3DB5-BE28-4CD0-BED5-B3EBE93DC68DQ37080513-592C0E85-9677-47B1-910A-D4D6EEBF3CA4Q37114360-CE3659D6-DAD9-4F2B-8EA0-52A3901B20B9Q37175519-A8C2A722-B9D9-43FE-A2B4-E744BDD0ACDCQ37175654-8930CFD5-9E42-4D12-A6E6-00E45DCF223B
P2860
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
EGFR tyrosine kinase domain mu ...... elium in lung cancer patients.
@en
EGFR tyrosine kinase domain mu ...... elium in lung cancer patients.
@nl
type
label
EGFR tyrosine kinase domain mu ...... elium in lung cancer patients.
@en
EGFR tyrosine kinase domain mu ...... elium in lung cancer patients.
@nl
prefLabel
EGFR tyrosine kinase domain mu ...... elium in lung cancer patients.
@en
EGFR tyrosine kinase domain mu ...... elium in lung cancer patients.
@nl
P2093
P1433
P1476
EGFR tyrosine kinase domain mu ...... elium in lung cancer patients.
@en
P2093
Adi F Gazdar
B Nebiyou Bekele
Hisayuki Shigematsu
Jack A Roth
John D Minna
Waun Ki Hong
Ximing Tang
P304
P356
10.1158/0008-5472.CAN-05-1705
P407
P577
2005-09-01T00:00:00Z